If you made any changes in Pure, your changes will be visible here soon.

Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

  • 9 Similar Profiles
Neoplasms Medicine & Life Sciences
Pediatrics Medicine & Life Sciences
Pharmacokinetics Medicine & Life Sciences
Rhabdomyosarcoma Medicine & Life Sciences
temozolomide Medicine & Life Sciences
Acute Myeloid Leukemia Medicine & Life Sciences
irinotecan Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2002 2024

osteosarcoma
immunotherapy
resistance mechanisms
irinotecan
Ifosfamide
Vincristine
Doxorubicin
Pediatrics
Medical Oncology
Pediatrics
Research

Research Output 1998 2019

Identification of aggressive Gardner syndrome phenotype associated with a de novo APC variant, c.4666dup

Kiessling, P., Dowling, E., Huang, Y., Ho, M. L., Balakrishnan, K., Weigel, B. J., Highsmith, W. E., Niu, Z. & Schimmenti, L. A., Apr 1 2019, In : Cold Spring Harbor molecular case studies. 5, 2

Research output: Contribution to journalArticle

Open Access
Gardner Syndrome
Phenotype
Tooth Abnormalities
APC Genes
Osteoma

The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children’s Oncology Group

Malempati, S., Weigel, B. J., Chi, Y. Y., Tian, J., Anderson, J. R., Parham, D. M., Teot, L. A., Rodeberg, D. A., Yock, T. I., Shulkin, B. L., Spunt, S. L., Meyer, W. H. & Hawkins, D. S., Jan 15 2019, In : Cancer. 125, 2, p. 290-297 8 p.

Research output: Contribution to journalArticle

temozolomide
Rhabdomyosarcoma
Drug Therapy
irinotecan
Vincristine
2 Citations (Scopus)

A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group

Chuk, M. K., Widemann, B. C., Minard, C. G., Liu, X., Kim, A. R., Bernhardt, M. B., Kudgus, R. A., Reid, J. M., Voss, S. D., Blaney, S., Fox, E. & Weigel, B. J., Aug 1 2018, In : Pediatric Blood and Cancer. 65, 8, e27077.

Research output: Contribution to journalArticle

Open Access
Neoplasms
Maximum Tolerated Dose
Pharmacokinetics
Proteinuria
Fatigue
4 Citations (Scopus)

A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)

Schafer, E. S., Rau, R. E., Berg, S., Liu, X., Minard, C. G., D'Adamo, D., Scott, R., Reyderman, L., Martinez, G., Devarajan, S., Reid, J. M., Fox, E., Weigel, B. J. & Blaney, S. M., Aug 1 2018, In : Pediatric Blood and Cancer. 65, 8, e27066.

Research output: Contribution to journalArticle

eribulin
Microtubules
Pharmacokinetics
Neutropenia
Neoplasms

A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children’s Oncology Group phase 1 and pilot consortium trial (ADVL1315)

Geller, J. I., Fox, E., Turpin, B. K., Goldstein, S. L., Liu, X., Minard, C. G., Kudgus, R. A., Reid, J. M., Berg, S. L. & Weigel, B. J., Dec 1 2018, In : Cancer. 124, 23, p. 4548-4555 8 p.

Research output: Contribution to journalArticle

Open Access
Vascular Endothelial Growth Factor Receptor
Protein-Tyrosine Kinases
Neoplasms
Pharmacokinetics
Hypertension